Septerna, Inc. is a biotechnology company focused on harnessing the potential of biopharmaceuticals to create innovative therapies for challenging diseases. The company specializes in drug discovery and development, utilizing advanced technologies and a deep understanding of cellular functions to address unmet medical needs, particularly in the fields of oncology and other serious health conditions. Through its cutting-edge research and development efforts, Septerna aims to transform scientific breakthroughs into effective treatments that can significantly improve patient outcomes and quality of life. Read More
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing
Today’s pre-market spotlight highlights a powerful mix of emerging growth companies driving innovation across key sectors including AI-powered Insurtech, mmWave wireless connectivity, smart wearables, clinical-stage biotech, and advanced weight loss solutions. From Health In Tech’s (NASDAQ: HIT) disruptive insurance platform to Peraso’s (NASDAQ: PRSO) wireless technology milestone, Allurion’s (NASDAQ: ALUR) FDA-ready program, Septerna’s (NYSE: SEPN) GPCR-based therapeutics, Quoin’s (NASDAQ: QNRX) progress in rare skin disease treatment and Innovative Eyewear’s (NASDAQ: LUCY) Smart Branded eyewear, these companies represent pivotal trends shaping the market in 2025. As investors seek early exposure to transformative technologies, these pre-market movers warrant close attention.
Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Septerna, Inc. (“Septerna” or “the Company”) (NASDAQ: SEPN) for violations of the securities laws.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN) on behalf of Septerna stockholders. Our investigation concerns whether Septerna has violated the federal securities laws and/or engaged in other unlawful business practices.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
